Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lymphocyte subpopulations in melanoma patients treated with dendritic cell vaccines.

Advances in experimental medicine and biology - 1 Jan 2007

Kadagidze Zaira G, Borunova Anna A, Zabotina Tatiana N

Abstract excerpt

The main goal of cancer immunotherapy is to induce or boost tumor-specific effector cells able to eliminate or reduce tumor progression. In this study, we characterized lymphocyte phenotypes in melanoma patients receiving dendritic cell (DC)-based vaccinotherapy. We found that several biological markers served as unfavorable prognostic factors for patients' response to therapy. This included decrease of CD4+ and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to CD3 Complex
Share to CD4-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8-Positive T-Lymphocytes

Share to Dendritic Cells

Share to Immunotherapy

Share to Lymphocyte Subsets

Share to Receptors, IgG

Source

Identifiers

PMID: 17713027
DOI: 10.1007/978-0-387-72005-0_41

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lymphocyte subpopulations in melanoma patients treated with dendritic cell vaccines.PMID 17713027Read ↗

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.Semantic proximity Read ↗

Reduced number and impaired function of circulating gamma delta T cells in patients with cutaneous primary melanoma.Semantic proximity Read ↗

Dendritic Cells and Their Role in Immunotherapy.Semantic proximity Read ↗

Comparative investigation of the effects of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells.Semantic proximity Read ↗

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.Semantic proximity Read ↗

Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.Semantic proximity Read ↗

Dendritic cell vaccines in melanoma: from promise to proof?Semantic proximity Read ↗

Identification of Melanoma-reactive CD4+ T-Cell Subsets From Human Melanoma Draining Lymph Nodes.Semantic proximity Read ↗

Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas.Semantic proximity Read ↗

Marked anti-tumor effects of CD8(+)CD62L(+) T cells from melanoma-bearing mice.Semantic proximity Read ↗

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.Semantic proximity Read ↗

Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.